A regimen of Roche's Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3
Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea
The European Commission has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant treatment for breast cancer, extending its lead over would-be rivals in the PARP inhibitor class
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), th
While Merck & Co's Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there's one category where it lags behind Roche's Tecentriq – treatment of early
Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market
